The Potential Impact of EIF4E3 and LARP1 on Tumor Immunity in Hepatocellular Carcinoma

作     者：ZHU Wen Li ZENG Hua HUANG Dan Ping OUYANG Wei Jun WEI Chun Shan TONG Guang Dong ZHU Wen Li;ZENG Hua;HUANG Dan Ping;OUYANG Wei Jun;WEI Chun Shan;TONG Guang Dong

作者机构：Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese MedicineShenzhen 518033GuangdongChina Department of Liver DiseaseShenzhen Traditional Chinese Medicine HospitalShenzhen 518033GuangdongChina 

出 版 物：《Biomedical and Environmental Sciences》 (生物医学与环境科学（英文版）)

年 卷 期：2023年第36卷第5期

页      面：469-475页

核心收录：

学科分类：0830[工学-环境科学与工程（可授工学、理学、农学学位）] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Carcinoma diagnosis treatment 

摘      要：Hepatocellular carcinoma(HCC) is a highly aggressive primary liver malignancy and the third most common cause of cancer-related deaths worldwide. Although early HCC can be treated through surgical resection, liver transplantation, and radical ablation, the early recurrence rate after treatment is 70%[1]. Systemic therapy, such as molecular-targeted agents, has made great advances in HCC treatment, but the optimal therapeutic approaches are still limited due to insidious onset and late diagnosis[2]. Therefore, efficient HCC treatment strategies should be developed urgently.